Parental KIR/HLA‐C Profiles and Reproductive Failure: A Phenotype‐Stratified Retrospective Analysis of Couples With Fertility Disorders
Obstetrics and Gynecology International · 2026-01 · 2026 (1)
DOI: 10.1155/ogi/4578815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obstetrics and Gynecology International, online erschienen am 14.07.2026. Verfasst von Karin Černá und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immunological Department, GENNET, Na Poříčí 26, Prague, Czech Republic. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Interactions between maternal killer‐cell immunoglobulin‐like receptors (KIR) and fetal human leukocyte antigen‐C (HLA‐C) play a key role in implantation and placentation, yet their clinical relevance remains controversial, partly due to heterogeneous phenotyping of reproductive failure. We conducted a retrospective observational study of 73 biologically comparable clinically referred couples undergoing reproductive immunology assessment. Couples involving donor gametes, surrogacy, or multiple male partners were excluded. Clinical phenotypes were classified as isolated recurrent implantation failure (RIF‐only), isolated recurrent pregnancy loss/adverse pregnancy outcome (RPL/APO‐only), combined RIF + RPL/APO, or no reproductive failure. Maternal KIR phenotype (AA vs. Bx) was determined by flow cytometry and genetically confirmed. Maternal and paternal HLA‐C genotypes were classified as C1C1, C1C2, or C2C2. Associations were assessed using univariable, age‐adjusted, and multivariable logistic regression models. Maternal KIR‐AA was present in 53.4% of women and was more frequent in the RIF‐only group than in the RPL/APO‐only group (56.8% vs. 35.3%). In age‐adjusted analysis, KIR‐AA was associated with increased odds of RIF (OR 2.35; p = 0.054), but not with RPL/APO. Maternal HLA‐C genotype showed an exploratory signal consistent with implantation outcomes: C1C2 (OR 0.28; p = 0.031) and C2C2 (OR 0.10; p = 0.002) were protective against RIF compared to C1C1. In multivariable models, maternal C2C2 remained independently protective (aOR 0.08; p = 0.0048). Paternal HLA‐C genotype showed no independent associations. In conclusion, immunogenetic effects in reproductive failure are phenotype‐specific and predominantly influence implantation rather than postimplantation pregnancy loss.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunological Department, GENNET, Na Poříčí 26, Prague, Czech Republic.
- Europe IVF International, Evropská 15, Prague, Czech Republic.
- Reprofit International Brno, Hlinky 48, Brno, Czech Republic.
- Department of Gynecology, Obstetrics and Neonatology, General University Hospital and First Faculty of Medicine, Charles University, Apolinářská 18, Prague, Czech Republic, cuni.cz.
ORCID-Profile: Karin Černá, Jana Voborská Neudeckerová, Pavel Otevřel, Dagmar Ivanická, Michal Koucký, Tereza Kovářová, Štěpánka Luxová
Zitieren
APA
Černá, K., Neudeckerová, J. V., Otevřel, P., Ivanická, D., Koucký, M., Kovářová, T., & Luxová, Š. (2026). Parental KIR/HLA‐C Profiles and Reproductive Failure: A Phenotype‐Stratified Retrospective Analysis of Couples With Fertility Disorders. Obstetrics and Gynecology International, 2026(1). https://doi.org/10.1155/ogi/4578815
Vancouver
Černá K, Neudeckerová JV, Otevřel P, Ivanická D, Koucký M, Kovářová T, et al. Parental KIR/HLA‐C Profiles and Reproductive Failure: A Phenotype‐Stratified Retrospective Analysis of Couples With Fertility Disorders. Obstetrics and Gynecology International. 2026;2026(1). doi:10.1155/ogi/4578815
BibTeX
@article{ern2026,
author = {Černá, Karin and Neudeckerová, Jana Voborská and Otevřel, Pavel and Ivanická, Dagmar and Koucký, Michal and Kovářová, Tereza and Luxová, Štěpánka},
title = {Parental KIR/HLA‐C Profiles and Reproductive Failure: A Phenotype‐Stratified Retrospective Analysis of Couples With Fertility Disorders},
journal = {Obstetrics and Gynecology International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ogi/4578815}
}
EUVIMED